Bladder cancer treatment depends on the type, stage, grade and risk characteristics of the tumour. For selected patients with non-muscle-invasive bladder cancer, BCG is an established bladder-directed immunotherapy that may be recommended after tumour removal.
Understanding why BCG is used, how it is given and what follow-up involves can help patients have more informed discussions with their urologist.
What Is BCG Therapy?
BCG stands for Bacillus Calmette–Guérin. It is a weakened form of Mycobacterium bovis used as a type of immunotherapy.
Unlike medicines that are given through a vein, BCG for bladder cancer is administered directly into the bladder through a catheter. It stimulates an immune response within the bladder that can act against abnormal cancer cells.
BCG has been used for many years in the management of selected non-muscle-invasive bladder cancers.
When Is BCG Used for Bladder Cancer?
BCG is primarily considered for selected cases of non-muscle-invasive bladder cancer (NMIBC).
This group includes tumours that have not invaded the bladder’s muscular wall. Depending on the tumour’s characteristics and risk category, BCG may be considered as part of treatment following removal of visible tumour tissue.
The decision is based on factors such as:
- Tumour stage
- Tumour grade
- Presence of carcinoma in situ
- Number of tumours
- Tumour size
- Previous bladder cancer history
- Response to earlier treatment
Not every person diagnosed with bladder cancer needs BCG. Treatment should be determined after appropriate evaluation and pathology review.
How Does BCG Work?
BCG works differently from conventional chemotherapy.
After being placed into the bladder, it stimulates the body’s local immune response. Immune cells are activated within the bladder environment and may recognise and attack abnormal cells.
The aim is to reduce the likelihood of bladder cancer returning and, in appropriate higher-risk cases, to reduce the risk of disease progression.
How Is BCG Given?
BCG is delivered through a urinary catheter directly into the bladder.
A commonly used induction approach involves weekly treatments over several weeks, although the exact schedule depends on the patient’s diagnosis, risk category, treatment response and the treating urologist’s protocol.
The medication remains in the bladder for a specified period before it is passed in urine. Patients receive specific instructions from their medical team regarding treatment-day precautions and aftercare.
What Happens Before BCG?
Before BCG treatment is started, the urologist reviews the diagnosis and pathology results.
Visible bladder tumours are generally removed first using TURBT (Transurethral Resection of Bladder Tumour) when indicated. The pathology report then provides important information about the tumour’s stage and grade and helps determine whether intravesical BCG is appropriate.
This is why the pathology report is an important part of planning bladder cancer treatment.
What Are Common Side Effects?
BCG is generally administered locally, but it can cause temporary urinary and flu-like symptoms.
Some patients may experience:
- Burning or discomfort while urinating
- Increased urinary frequency
- Urinary urgency
- Mild blood in the urine
- Tiredness
- Mild fever or flu-like symptoms
The severity and duration of symptoms vary from person to person.
Patients should follow their urologist’s instructions and report significant or persistent symptoms. Severe fever, worsening illness, difficulty passing urine or other concerning symptoms require prompt medical assessment.
Is BCG a One-Time Treatment?
BCG is generally given as a course of treatment rather than a single instillation.
An initial induction course may be followed by additional treatment or maintenance therapy depending on the individual’s bladder cancer risk and response.
Some established treatment protocols use weekly instillations during an induction period followed by additional scheduled courses in appropriate patients.
The treatment schedule should not be assumed to be the same for every patient.
Why Is Follow-Up Important After BCG?
Bladder cancer can recur, which makes ongoing monitoring an important part of care.
Follow-up may involve examinations such as:
Cystoscopy
A cystoscopy allows the urologist to inspect the inside of the bladder for recurrent or persistent abnormalities.
Urine-Based Tests
Urine cytology or other investigations may be recommended depending on the clinical situation.
Additional Evaluation
If symptoms, cystoscopy findings or pathology raise concerns, further testing or treatment may be required.
The follow-up plan is individualised according to the patient’s risk and previous treatment.
What If Bladder Cancer Returns After BCG?
A recurrence after BCG does not mean that every patient requires the same next treatment.
The urologist considers factors including:
- When the recurrence occurred
- The type and grade of the tumour
- Previous BCG exposure
- Response to earlier treatment
- Whether the disease is classified as BCG-unresponsive
- Overall health and treatment preferences
Patients with persistent or recurrent high-risk disease after adequate BCG may require a different treatment strategy. Further management can include additional bladder-directed treatment, clinical trials or surgery in selected situations.
BCG vs Other Bladder Cancer Treatments
BCG is only one component of bladder cancer management.
Depending on the diagnosis, treatment may include:
- TURBT
- Intravesical chemotherapy
- Intravesical BCG
- Surveillance cystoscopy
- Additional bladder procedures
- Systemic treatment
- Major surgery for selected advanced or high-risk cases
The appropriate option depends on the tumour’s characteristics and the patient’s overall clinical condition.
When Should You See a Urologist?
Blood in the urine, recurrent urinary symptoms or an abnormal bladder finding should be appropriately evaluated.
Bladder cancer can present with symptoms that may also occur in less serious urinary conditions, so symptoms alone cannot establish a diagnosis.
If you have been diagnosed with bladder cancer or advised to consider BCG, discuss the pathology report, treatment objective, expected schedule and follow-up plan with your urologist.
Bladder Cancer Care in Pune
Dr. Rakshit Ahuja is a Urologist in Pune providing evaluation and treatment for bladder and other urological conditions.
Patients diagnosed with bladder tumours can discuss their pathology findings and available treatment options with their treating urologist to understand the most appropriate approach for their individual condition.
Dr. Rakshit Ahuja
Google Business Profile: Dr. Rakshit Ahuja
Clinic Address:
The Space – Business Complex, 401, Rajaram Patil Nagar, Vitthal Nagar, Kharadi, Pune, Maharashtra 411014
Contact: +91 9890583933
Website: www.drrakshitahujaurologist.com
Conclusion
BCG is an important immunotherapy used in selected patients with non-muscle-invasive bladder cancer. It is administered directly into the bladder and works by stimulating an immune response against abnormal cells.
However, BCG is not appropriate for every bladder cancer patient. The tumour’s stage, grade, risk category, previous treatment and response all influence treatment decisions.
Regular follow-up is also essential because bladder cancer can recur. Working closely with a qualified urologist can help ensure that treatment and monitoring are tailored to the individual’s diagnosis.